5-HT receptors as targets for the development of novel anxiolytic drugs: models, mechanisms and future directions

Psychopharmacology

Volumn 112, Issue 1, 1993, Pages 1-12

  Barrett, James E ^a   Vanover, Kimberly E ^a  

^a WYETH RESEARCH   (United States)

Author keywords

5 HT; 5 HT1A; 5 HT1C 2; 5 HT3; 8 OH DPAT; Animal models; Anxiety; Anxiolytic drugs; Buspirone; Flexinoxan; Ipsapirone; Pigeon; Tandospirone

Indexed keywords

1 (7 METHOXY 1 NAPHTHYL) 4 [2 (2 THENOYLAMINO)ETHYL]PIPERAZINE; 1 [2 (4 FLUOROBENZAMIDO)ETHYL] 4 (7 METHOXY 1 NAPHTHYL)PIPERAZINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 8 [2 [(2,3 DIHYDRO 1,4 BENZODIOXIN 2 YL)METHYLAMINO]ETHYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE MESYLATE; ADATANSERIN; ALNESPIRONE; ANXIOLYTIC AGENT; BUSPIRONE; FLESINOXAN; GEPIRONE; IPSAPIRONE; RECEPTOR SUBTYPE; SEROTONIN 1A RECEPTOR; SEROTONIN 1C RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SEROTONIN RECEPTOR AFFECTING AGENT; TANDOSPIRONE; ZALOSPIRONE;

ANIMAL EXPERIMENT; ANXIETY NEUROSIS; BEHAVIOR; DRUG DEVELOPMENT; DRUG MECHANISM; HUMAN; NONHUMAN; PIGEON; PRIORITY JOURNAL; REVIEW;

ANIMAL; ANTI-ANXIETY AGENTS; HUMAN; MODELS, PSYCHOLOGICAL; RECEPTORS, SEROTONIN; SEROTONIN AGENTS;

EID: 0027208571     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/BF02247357     Document Type: Review

References (107)

1. WY-50,324
2. Blockade of acquisition of drug-conditioned place aversion by 5-HT3 antagonists
3. Facilitation of 8-OH-DPAT-induced forepaw treading of rats by the 5-HT2 agonist DOI
4. Functional interaction between serotonin-S2 and dopamine-D2 neurotransmission as revealed by selective antagonism of hyper-reactivity to tryptamine and apomorphine
5. Behavioural evidence for a functional interaction between central 5-HT2 and 5-HT1A receptors
6. The differential activities of R(+)- and S(−)-zacopride as 5-HT3 receptor antagonists
7. The effects of ondansetron, a 5-HT3 receptor antagonist, on cognition in rodents and primates
8. Behavioural pharmacology of 5-HT3 receptor ligands
9. Animal behavior models in the analysis and understanding of anxiolytic drugs acting at serotonin receptors
10. Studies on the effects of 5-HT1A drugs in the pigeon
11. Anxiolytic effects of 5-HT1A agonists, 5-HT3 antagonists and benzodiazepines
12. Buspirone in animal models of anxiety
13. Anticonflict and discriminative stimulus effects of the 5-HT1A compounds WY-47,846 and WY-48,723 and the mixed 5-HT1A agonist/5-HT2 antagonist WY-50,324 in pigeons
14. Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice
15. Risk assessment and animal models of anxiety
16. Agonist/antagonist interactions with cloned human 5-HT1A receptors: variations in intrinsic activity studied in transfected HeLa cells
17. The role of serotonin in anxiety: Behavioural approaches
18. Comparative studies on the anti-punishment effects of chlordiazepoxide, buspirone and ritanserin in the pigeon, Geller-Seifter and Vogel conflict procedures
19. The influence of ritanserin, a double-blind placebo-controlled study versus lorazepam
20. Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects
21. Animal models of anxiety: the effect of compounds that modify 5-HT neurotransmission
22. S 14506: a novel, potent, high-efficacy 5-HT1A agonist and potential anxiolytic agent
23. Anxiolytic effects of 5-HT3 antagonists in animals
24. Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain
25. Zacopride: anxiolytic profile in rodent and primate models of anxiety
26. Exploration of mice in a black and white test box: Validation as a model of anxiety
27. Behavioural effects in gerbils of the 5-HT3 receptor antagonists, BRL 43694 and ICS 205-930, under circumstances of high and low light intensity
28. An ethological study of the effects of buspirone and the 5-HT3 receptor antagonist, BRL 43694 (granisetron) on behaviour during social interactions in female and male mice
29. Chronic administration of the 5-HT3 receptor antagonist BRL 43694; effects on reflex epilepsy and social behaviour of the Mongolian gerbil
30. Do functional relationships exist between 5-HT1A and 5-HT2 receptors?
31. 5-HT mechanisms in human anxiety
32. 5-HT1A receptors in anxiety
33. Preclinical anxiolytic versus antipsychotic profiles of the 5-HT3 antagonists ondansetron, zacopride, 3α-tropanyl-1H-indole-3-carboxylic acid ester, and 1αH, 3α, 5αH-tropan-3-yl-3,5-dichlorobenzoate
34. Reduction in cortical 5-HT2 receptor sensitivity after continuous gepirone treatment
35. Buspirone in the management of major depression: a placebo-controlled comparison
36. Lack of effects of 5-HT3 receptor antagonists in the social interaction and elevated plus-maze tests of anxiety in the rat
37. Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. A meta-analysis of eight randomized, controlled studies
38. Behavioral studies with anxiolytic drugs. VI. Effects on punished responding of drugs interacting with serotonin receptor subtypes
39. Anxiolytic profile of GR 38032F in the potentiated startle paradigm
40. Multiple populations of serotonin receptors may modulate the behavioral effects of serotonergic agents
41. Effects of the 5-HT3 antagonist GR38032F (ondansetron) on benzodiazepine withdrawl in rats
42. Blockade of the discriminative stimulus effects of ethanol with 5-HT3 receptor antagonists
43. Novel anxiolytics that act as partial agonists at benzodiazepine receptors
44. The main features of central 5-HT1 receptors
45. Molecular biology of serotonin receptors
46. Molecular biology of the 5-HT1 receptor subfamily
47. Preclinical profile of the pyrimidinylpiperazinyl imide compound WY47,846: a potential anxiolytic
48. A quantitative autoradiographic study of serotonin1A receptor regulation. Effect of 5,7-dihydroxytrtyptamine and antidepressant treatments
49. Evidence that the amygdala is involved in the disinhibitory effects of 5-HT3 receptor antagonists
50. Effects of buspirone in the Geller-Seifter conflict test with incremental shock
51. Molecular characterization of three serotonin receptor subtypes
52. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties
53. The potential anxiolytic activity of GR38032F, a 5-HT3-receptor antagonist
54. The potent 5-HT3 receptor antagonist (R)-zacopride labels an additional high affinity site in the central nervous system
55. Effects of anxiolytic and anxiogenic drugs on exploratory activity in a simple model of anxiety in mice
56. Zacopride, a 5-HT3 receptor antagonist, reduces voluntary ethanol consumption in rats
57. Behavioral pharmacology of antagonists at 5-HT2/5-HT1C receptors
58. Pharmacological validation of a novel animal model of anticipatory anxiety in mice
59. Ethologically-based animal models of anxiety disorders
60. 5-HT1 receptors and behavior
61. 5-Hydroxytryptamine1A receptors and behavioral rersponses
62. Receptor reserve for 5-hydroxytryptamine1A-mediated inhibition of serotonin synthesis: possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists
63. Targeting multiple serotonin receptors: Mixed 5-HT1A agonists/5-HT1C/2 antagonists as therapeutic agents
64. S 14671: A naphthylpiperazine 5-hydroxytryptamine1A agonist of exceptional potency and high efficacy possessing antagonist activity at 5-hydroxytryptamine1C/2 receptors
65. Behavioural effects of 5-HT3 antagonists in animal models for aggression, anxiety and psychosis
66. Characterization of MDL 7300EF as a 5-HT1A selective ligand and its effects in animal models of anxiety: comparison with buspirone, 8-OH-DPAT and diazepam
67. Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers
68. Effects of buspirone and other anxiolytics on punished key-pecking in the pigeon
69. The effects of 5-HT receptor ligands on ultrasonic calling in mouse pups
70. The discovery and development of buspirone: a new approach to the treatment of anxiety
71. Regulation of 5-hydroxytryptamine1A receptor function in rat hippocampus by short- and long-term administration of 5-hydroxytryptamine1A agonists and antidepressants
72. Anxiety and its therapy: today and tomorrow
73. Serotonergic receptors in anxiety and aggression; evidence from animal pharmacology
74. Neuropharmacological and physiological validation of a computer-controlled two-compartment black and white box for the assessment of anxiety
75. Similar effects of diazepam and the 5-HT3 receptor antagonist ICS 205-930 on place aversion conditioning
76. Platelet [3H]-paroxetine and [3H]-imipramine binding in zacopride-treated patients with generalized anxiety disorder: preliminary results
77. Antagonism of [3H]-zacopride binding to 5-HT3 recognition sites by its (R) and (S) enantiomers
78. Effects of drugs on punished behavior: pre-clinical tests for anxiolytics
79. Cork gnawing in the rat as a screening method for buspirone-like anxiolytics
80. Effects of tandospirone in three behavioral tests for anxiolytics
81. The relation of central 5-HT1A and 5-HT2 Receptors: low dose agonist-induced selective tolerance in the rat
82. Autoradiography of serotonin receptor subtypes in the central nervous system
83. Clinical effects of 5-HT1A partial agonists, buspirone and gepirone in the treatment of depression
84. The effects of buspirone and related compounds on suppressed operant responding in rats
85. Animal models of anxiety and the screening and development of novel anxiolytic drugs
86. Increased rates of punished responding produced by buspirone-like compounds in rats
87. Alterations of central serotoninergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: biochemical and electrophysiological studies
88. 5-HT1A receptor ligands in animal models of anxiety, impulsivity and depression: multiple mechanisms of action?
89. Biochemical measurement of serotonergic neurotransmission in vivo: effect of antidepressant and anxiolytic treatments
90. Chronic administration of buspirone down-regulates 5-HT2 receptor binding sites
91. Pharmacological and clinical effects of buspirone
92. Latency to enter a mirrored chamber: a novel behavioral assay for anxiolytic agents
93. Molecular basis of buspirone's anxiolytic action
94. Anxiety and depression
95. The (S)-isomer of [3H]zacopride labels 5-HT3 receptors with a high affinity in rat brain
96. Behavioral effects of acute and chronic buspirone
97. Anxiogenic-like effect of infusing 1-(3-chlorophenyl) piperazine (mCPP) into the hippocampus
98. Serotonin and animal behavior
99. Serotonergic modulation of the rat pup ultrasonic isolation call: studies with 5HT1 and 5HT2 subtype-selective agonists and antagonists
100. Anticonflict effects of buspirone and chlordiazepoxide in pigeons under a concurrent schedule with punishment and a changeover response
101. Comparison of acute and chronic treatment of various serotonergic agents with those of diazepam and idazoxan in the rat elevated X-maze
102. Neurochemistry and neurophysiology of buspirone and gepirone: Interactions at presynaptic and postsynaptic 5-HT1A receptors
103. 8-OH-DPAT and buspirone analogs inhibit the ketanserin-sensitive quipazine-induced head shake response in rats
104. Lack of apparent receptor reserve at postsynaptic 5-hydroxytryptamine1A receptors negatively coupled to adenylyl cyclase activity in rat hippocampal membranes
105. Anxiolytic-like activity of R(+)- and S(−)-zacopride in mice
106. 5-Hydroxytryptamine receptors